Upgrade to SI Premium - Free Trial

UBS Reiterates Neutral Rating on CME Group (CME), Raises Q1 Estimates

April 6, 2026 9:33 AM
UBS analyst Alex Kramm reiterated a Neutral rating and $310.00 price target on CME Group (NASDAQ: CME).The analyst commented, "Following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments